Filing summary
Entity note: The supplied filing is ARCA biopharma, Inc.’s Form 10-Q, not an Oruka Therapeutics, Inc. filing. It covers the quarter ended September 30, 2020; financial statements are unaudited.
Business context
ARCA is a clinical-stage biopharmaceutical company with no product revenue to date. Its principal programs are AB201 (rNAPc2), then planned for development as a COVID-19 treatment, and Gencaro for atrial fibrillation in selected heart-failure patients. AB171 is an earlier-stage candidate.
Financial performance and liquidity
| Metric | Q3 2020 | Q3 2019 | Nine months 2020 | Nine months 2019 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $1.051 million | $0.347 million | $1.788 million | $1.449 million |
| General and administrative expense | $0.939 million | $0.900 million | $2.852 million | $3.087 million |
| Operating loss | $1.990 million | $1.247 million | $4.640 million | $4.536 million |
| Net loss | $1.991 million | $1.156 million | $4.613 million | $4.256 million |
| Net loss per share, basic and diluted | $0.33 | $0.76 | $1.46 | $3.46 |
| Operating cash used | Not separately stated | Not separately stated | $4.730 million | $3.643 million |
At September 30, 2020, cash and cash equivalents were $51.095 million, compared with $8.363 million at year-end 2019. Total current assets were $51.936 million and current liabilities were $1.527 million; stockholders’ equity was $50.455 million. The filing reports minimal interest expense and no material conventional debt balance; it does report vendor-finance repayments and a new office lease with a stated present value of $442,000.
Cash increased by $42.732 million in the first nine months, primarily from $47.468 million of net financing cash flow, offset by operating and investing outflows. Financing included stock sales. Shares outstanding increased from 1.594 million at December 31, 2019 to 9.286 million at September 30, 2020, representing substantial dilution.
Changes versus prior periods
- Q3 research and development expense rose about $0.7 million year over year, reflecting initial AB201 trial costs and higher clinical, manufacturing-development, and outside-services costs.
- Nine-month research and development expense increased about $0.3 million, while general and administrative expense declined about $0.2 million.
- Q3 net loss widened by $0.835 million; the nine-month net loss widened by $0.357 million.
- Operating cash use increased by $1.087 million year over year for the nine-month period.
- Equity financing materially strengthened cash but increased the share count. The filing says approximately $25.3 million remained available under the July 2020 at-the-market program as of September 30.
Outlook, risks, and notable items
- Management expected September 30 cash to fund operations through 2022, including the planned AB201 Phase 2b trial. This is an estimate dependent on assumptions; management cautioned that cash use could differ and additional capital may be needed.
- The FDA had approved AB201’s investigational new drug application in October 2020. ARCA planned to begin the approximately 100-patient Phase 2b ASPEN-COVID-19 study in Q4 2020 and anticipated topline data in Q2 2021. AB201 had not been tested in COVID-19 patients or preclinical COVID-19 models.
- ARCA had put the planned Gencaro PRECISION-AF Phase 3 trial on hold, citing COVID-19 and prioritization of AB201. Restarting it depended on significant additional financing.
- Management was pursuing financing and potential partnering or other strategic transactions. Failure to obtain funding could delay or stop development or operations. The filing also recounts substantial doubt about going concern raised in connection with the 2019 annual financial statements; management’s current runway expectation does not eliminate funding risk.
- Key risks include clinical and regulatory uncertainty, AB201 enrollment and efficacy, competition from COVID-19 vaccines and therapies, reliance on contract research and manufacturing organizations, Gencaro’s need for genetic testing, dilution from future equity sales, and Nasdaq listing requirements.
- COVID-19 was not expected by management to have a material financial effect at that time, but a prolonged severe crisis could adversely affect operations, trials, financing, and cash flows.
- The prior office lease expired September 30, 2020. A replacement lease began October 1, 2020 for 42 months; the filing’s estimated present value of lease payments was $442,000.
Important facts for investors to verify
- Confirm the intended issuer: this filing is for ARCA biopharma, Inc. (ticker ABIO), not Oruka Therapeutics, Inc.
- Check subsequent filings for whether the AB201 trial began on schedule, enrollment progress, safety findings, and reported results.
- Verify cash runway against actual operating burn, further ATM sales, and any partnering or financing transactions; assess the resulting dilution.
- Track whether Gencaro’s paused Phase 3 trial receives funding and resumes, and whether the companion diagnostic path remains viable.
- Review subsequent disclosures on Nasdaq listing compliance and any change in management’s going-concern assessment.